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Abstract Alzheimer’s disease (AD) is one key medical
challenge of the aging society and despite a great amount
of effort and a huge collection of acquired data on molecular
mechanisms that are associated with the onset and progres-
sion of this devastating disorder, no causal therapy is in
sight. The two main hypotheses of AD, the amyloid cascade
hypothesis and the Tau hypothesis, are still in the focus of
AD research. With aging as the accepted main risk factor of
the most important non familial and late onset sporadic
forms of AD, it is now mandatory to discuss more inten-
sively aspects of cellular aging and aging biochemistry and
its impact on neurodegeneration. Since aging is accompa-
nied by changes in cellular protein homeostasis and an
increasing demand for protein degradation, aspects of pro-
tein folding, misfolding, refolding and, importantly, protein
degradation need to be linked to AD pathogenesis. This is
the purpose of this short review.
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Introduction
Alzheimer’s disease (AD) is a progressive neurodegenera-
tive disorder starting with mild memory loss and manifest-
ing in severe cognitive decline. Neuropathologically, the
disease is characterized by an extensive deposition of Am-
yloid β (Aβ) peptides in extracellular amyloid plaques and
by intracellular neurofibrillary tangles (NFTs) of hyper-
phosphorylated Tau protein [1]. Sporadic late-onset AD is
the most common form of dementia in the elderly and is
strongly associated with age. In rare cases (<5%), AD is
inherited and results in an early disease onset. One genetic
risk factor for late-onset AD that has been reported through-
out many studies is Apolipoprotein E (ApoE) which phys-
iologically functions as a ligand in receptor-mediated
endocytosis of lipoprotein particles [2, 3]. Several single
nucleotide polymorphisms in apoE lead to alterations in
the coding sequence and result in three common isoforms
called apoE2, apoE3 and apoE4 with the E4 allele being an
AD risk factor and E2 being protective [4–6]. Strong evi-
dence suggests that ApoE influences AD via its effect on
Aβ metabolism; however, the details of this process have to
be fully elucidated. Positional cloning studies of familial
AD (FAD) cases have identified mutations in three genes,
amyloid precursor protein (app), presenilin 1 and 2 (ps1,
ps2), which are tightly linked to the generation of Aβ
peptides [7]. Proteolytic processing of amyloid precursor
protein (APP) by BACE (β-site APP cleaving enzyme) is
followed by cleavage by γ-secretase containing presenilins
and results in the release of Aβ peptides of different length.
Aβ40 and Aβ42 (40 or 42 amino acids, respectively) are the
most prominent Aβ peptides and since the C-terminus has
important implication for toxicity, the longer Aβ42 peptide
exhibits stronger neurotoxic properties. The FAD-linked
mutations cause an elevated production of amyloidogenic
Aβ, which is the basis for the amyloid hypothesis of AD,
stating that Aβ peptides are the key-players in neuronal
dysfunction and subsequent neurodegeneration in AD [8].
Recently, it has been suggested that the soluble oligomeric
forms of Aβ42 are the potentially harmful species and that
these oligomers affect various important cellular mecha-
nisms, resulting in decreased functionality and survival of
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neuronal cells [9]. However, Aβ peptides are not exclusive-
ly generated under pathological conditions as they are part
of the normal cellular metabolism and a significant load of
amyloid plaques is also observed in brains of healthy aged
individuals [10, 11]. This challenges the amyloid hypothesis
of AD and up to date the nature of the disease-relevant
alteration in aged neurons remains unclear.
Although Alois Alzheimer already described protein
deposits in the brain of demented patients, the question
why distinct proteins that are potentially causative for the
disease accumulate in discrete brain regions in the course of
aging remains unanswered. Today, we know that the pro-
gressive deposition of misfolded and aggregation-prone pro-
teins in defined regions of the nervous system is not unique
to AD, but a well-described characteristic of several neuro-
degenerative disorders, including Parkinson’s disease (PD),
Huntington’s disease (HD) and Amyotrophic Lateral Scle-
rosis (ALS) [12]. Recently, it has been proposed that the
accumulation of disease-relevant proteins in aggregates
might actually even be considered as a protective mecha-
nism to dispose these proteins and remove them from the
cellular metabolism [13, 14]. Generally, within the crowded
cellular environment, proteins are always at risk for dena-
turation. Changing genetic and environmental factors, as
during pathology or aging, challenge the integrity of the
cellular protein homeostasis (proteostasis). Therefore, the
stability and metabolism of the proteome needs to be con-
trolled carefully and is carried out by a complex network of
several hundred evolutionarily conserved proteins. This net-
work, including molecular chaperones, the ubiquitin–pro-
teasome system (UPS) and the autophagy system is
stringently regulated and indispensable for the maintenance
of proteostasis. All main players of this network are ubiqui-
tously expressed and consequently also present in neuronal
tissue.
Molecular chaperones, most be prominently represented
by the heat shock protein 70 (HSP70) family and their
regulators, are responsible for correct folding and refolding
of proteins as well as for the transport of misfolded proteins
to the protein-degradation systems [15]. The chaperone
network is controlled by the activity of transcription factors,
e.g. heat shock transcription factor 1 (HSF1), which rapidly
adjusts the cellular chaperone capacity during stress condi-
tions. The UPS is the major protein-degradation machinery
of the cell and controls the metabolism of cytosolic proteins
and the degradation of misfolded proteins. Proteins that are
destined for proteasomal degradation become specifically
tagged with the protein ubiquitin in a well-organized enzy-
matic cascade [16]. Interestingly, also a ubiquitin-
independent way of proteasomal degradation has been de-
scribed recently that mostly involves small and misfolded
proteins [17]. As an additional mechanism for protein deg-
radation the term autophagy summarizes degradation
pathways that deliver their substrates to the lysosome [18].
The major autophagic systems described so far are macro-
autophagy and chaperone-mediated autophagy (CMA).
Macroautophagy is a complex process that involves the
formation of a membrane structure, the autophagosome,
which engulfs bulk cellular material (proteins and organ-
elles) and subsequently fuses with the lysosome. CMA
involves the constitutively expressed heat shock cognate
70 (HSC70) that targets client proteins with a specific con-
sensus motif directly to the lysosome [19]. In fact, HSP70 is
also an important factor to assure selectivity of macroau-
tophagy of degradation-prone proteins in a distinct pathway,
mediated via the co-chaperone BCL2-associated athanogene
3 (BAG3) [20].
Aging and disease challenge the proteostasis network and
the accumulation of instable proteins results in wide-spread
protein aggregation [21, 22]. Our discussion presented here
attempts to integrate two major factors that are associated
with neurodegeneration, protein homeostasis and aging.
Most importantly, we focus on the role of specific pathways
which are needed to restore and maintain proteostasis during
aging and their interplay with a special focus on impaired
proteostasis in AD, which may add to a novel view and
understanding of AD pathogenesis. Since recently many
excellent reviews on various aspects providing in depth
discussions have been presented, we are concentrating here
on the integration of these different aspects. Therefore, we
frequently refer to review work with the recommendation of
further reading rather than trying to fully cover the discussed
issues by their original publications.
Maintenance of Proteostasis via Molecular Chaperones:
the First Line of Defense Against Protein Misfolding
Cells permanently encounter the problem to maintain the
integrity and functionality of the proteome. Within the
crowded cellular environment, the correct conformation of
proteins must be controlled and misfolded and irreversibly
damaged proteins must be efficiently refolded or removed.
Central players of the protein homeostasis system are mo-
lecular chaperones that sense misfolded proteins and, when
refolding fails, direct them to the protein-degradation path-
ways. Molecular chaperones are specified as proteins that
interact with and participate in folding or refolding of non-
native proteins. Therefore, chaperones help unfolded pro-
teins to achieve their functional conformation without being
present in the final structure [15, 23–27]. They exert a
multitude of activities, including de novo folding, refolding
of denatured proteins, transport to subcellular compart-
ments, oligomeric assembly and disposal by proteolytic
degradation [28, 29]. Different classes of chaperones work
together to form co-operative networks and are often termed
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heat shock proteins (HSPs), because they are sensitively up-
regulated under stress conditions in which the amount of
misfolded proteins is increased [30]. Chaperones, which are
involved in protein folding and refolding, such as HSP70,
HSP90 and chaperonin (HSP60), promote folding activity
through ATP/cofactor-regulated binding and release cycles
[15, 31]. They recognize short hydrophobic amino acid
stretches of misfolded proteins and can co-operate with
ATP-independent chaperones, e.g. small HSPs (sHSPs), to
prevent protein aggregation.
HSP70 proteins are central players in proteostasis control
and increasing HSP70 levels prevent protein aggregation in
various disease models that are based on the expression of
aggregation-prone proteins [32, 33]. The activity of HSP70
is ATP dependent and is controlled by chaperones of the
HSP40 family as well as nucleotide exchange factors
(NEFs) [34, 35]. After ATP hydrolysis, a NEF binds to the
ATPase domain of HSP70 and catalyzes the nucleotide
exchange, which results in substrate release. Thus, chaper-
one binding to the hydrophobic region of misfolded proteins
transiently blocks aggregation and the subsequent ATP-
dependent release allows controlled folding of the client
protein. HSP40/DNAJs, HSC70-interacting protein (HIP),
BCL2-associated athanogene 1 (BAG1) and BAG3 are
prominent co-chaperones that control the ATP-dependent
activity of HSP70. DNAJ proteins generally enhance the
ATPase activity of HSP70, but their action can lead to
different fates of their bound substrates. DNAJB1 is an
example for a DNAJ protein that supports substrate folding,
whereas DNAJB2-bound clients are degraded by the pro-
teasome [36]. The co-chaperone HIP stabilizes the ADP-
bound state of HSP70 and co-operates with HSP70 in pro-
tein folding. BAG1 inhibits the HSP70 chaperone activity,
competing with the stimulatory action of HIP [37]. Other
HSP70-binding cofactors are the ubiquitin ligases carboxy
terminus of HSC70-interacting protein (CHIP) and PAR-
KIN, which provide a link between HSP70, co-chaperones
and the UPS, resulting in client ubiquitination and degrada-
tion by the proteasome [34, 38, 39]. Recently, it has been
shown that BAG3 interacts with HSP70 and directs the
chaperone and its substrates into the autophagic pathway,
providing an association of HSP70, co-chaperones and
autophagy [40]. An extensive description of the HSP70
machinery, the exact structure-function relationship between
HSP70 and its various cofactors, has been excellently
reviewed elsewhere [34].
The functional variability of the chaperone system that is
exerted by a multitude of single proteins highlights the
complexity of this proteostasis network. However, limited
knowledge exists on the exact composition and capacity of
the chaperone system within a cell or a certain tissue. A
general view assumes that total levels of cellular chaperones
exceed the actual requirements and that a sufficient amount
of chaperones is free of clients. Thus, the network has
excess capacity to initially deal with sudden additional
chaperone requirements, as exhibited during stress condi-
tions [41]. An opposite view proposes that the capacity of
the chaperone network is always closely titrated to the actual
demand of chaperone activity and that the system is other-
wise rapidly adapted to conditions of increased requirements
[41]. The analysis of the chaperone capacity of neuronal and
muscular tissue of Caenorhabditis elegans (C. elegans)
demonstrates that these tissues indeed display different fold-
ing activities and that neurons are particularly sensitive to
protein denaturation during heat stress [42]. However, the
adaptation of the chaperone network during aging is critical
as it is well acknowledged that protein aggregation and
disruption of proteostasis are characteristic for aged cells
[21]. Several studies have clearly implicated a role of chap-
erones in aging. The periodical application of mild heat
stress decreases mortality in Drosophila melanogaster and
C. elegans, which is mediated by HSP70 activity and the
overexpression of HSP70 in C. elegans increases the life
span of the nematode [43–45]. Several reports have ana-
lyzed chaperone protein or mRNA levels in aged cells and
found increased or basal amounts, whereas the stress-
mediated induction of chaperone expression is impaired.
The transcription of chaperone genes in response to stress
conditions is controlled by the transcription factor HSF1,
which shows an impaired DNA-binding potential in aged
cells [46]. A reduced activity of HSF1 in C. elegans results
in a shortened life span and, conversely, the enhanced ex-
pression of the transcription factor increases the life span.
HSF1 activity is also essential for the extended life span of
the extremely long-lived daf-2/Insulin/IGF-1 receptor
mutants of C. elegans [47, 48]. Thus, HSF1 and chaperone
activity can promote longevity, demonstrating a clear asso-
ciation of chaperones, proteostasis and aging.
Molecular Chaperones Get in Touch with the Protein
Degradation Machineries
Some of the factors mentioned so far are involved in linking
chaperone functions with cellular protein-degradation path-
ways, the UPS and autophagy, for the removal of misfolded
proteins. Besides protein aggregation, one factor that indu-
ces ubiquitination is protein damage caused by free radical
oxygen species (ROS) and oxidative stress. Most likely,
irreversible oxidation may activate chaperones and the
UPS to induce protein repair of misfolded proteins and lead
to ubiquitination and protein degradation. During aging,
mitochondria are affected and produce increasing amounts
of ROS. In particular, the mitochondrial respiratory chain is
strongly linked to the production of ROS and as one conse-
quence may cause protein dysfunction, apoptosis, necrosis,
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aging and disease [49, 50]. Protein oxidation leads to a
change in protein conformation and function and chaper-
ones may sense such changes and in turn activate the UPS as
a quality control system. Depending on the degree of oxi-
dation, irreversible oxidation and loss of protein function
may lead to degradation and/or accumulation of damaged
proteins and to the formation of so-called aggresomes,
which display a high autophagic activity [51, 52].
The UPS is a complex enzymatic pathway that starts with
the ligation of ubiquitin, a 76-amino-acid-long and highly
conserved protein, to other cellular proteins and thus labels
them for degradation. This process consists of three steps.
Initially the C-terminal end of ubiquitin is activated by ATP-
dependent phosphorylation and formation of a thiol ester via
an activating enzyme, E1. It is then transferred to a thiol
group of an ubiquitin-carrier protein, E2. The E3 ligase
directs ubiquitin from E2 to an ε-amino group of the target
protein [53, 54]. The C-terminus of an additional ubiquitin
protein can be ligated onto one of the seven lysine residues
within the attached ubiquitin molecule. For degradation via
the proteasome, target proteins need to be polyubiquitinated.
Ubiquitin–ubiquitin linkages between either the C-terminus
and lysine residues K48 or K63 are the major recognition
signals for proteasomal degradation. Ubiquitin chains also
occur among other lysine residues, whereas ubiquitin exten-
sion via K6 is associated with DNA repair, K11 with endo-
plasmatic reticulum-associated protein degradation and cell
cycle regulation, K27 with ubiquitin fusion degradation,
K29 with lysosomal degradation and K33 with kinase mod-
ification [55]. Monoubiquitination can modify the activity
of the protein transport machinery and when attached to
transmembrane proteins can serve as a sorting signal to
direct their movement between different cellular compart-
ments [56–59]. The polyubiquitinated proteins destined for
degradation are processed by the multienzymatic protea-
some complex: first they become deubiquitinated and then
degraded by the 26S proteasome, a system that is composed
of various proteasome subunits. The eukaryotic 20S protea-
some core complex consists of four heptameric rings com-
prising two classes of seven non-identical but homologous
subunits. The outer rings contain alpha-type subunits with
gating function for substrate entrance and product release,
while the beta-subunits exhibit peptide hydrolyzing activity.
The 19S regulatory complex binds to the 20S catalytic core
in a flexible manner and consists of six ATPases, forming a
ring at the entrance of the core and exerting chaperone-like
activity [60].
The UPS is the major degradation system in the cell for
the degradation of short-lived, misfolded and defective pro-
teins. An accumulation of polyubiquitinated proteins is
reported for numerous neurological disorders [61], which
suggests that UPS dysfunction plays a prominent role in the
pathogenesis of neurodegenerative diseases and moreover in
aging [62]. Since proteasomal activity decreases during
aging over all, the degradation demand of the cell increases,
which results in an age-associated induction of the autophagy
pathway that delivers substrates for degradation ultimately to
lysosomes [20, 63].
Autophagy is negatively regulated via the evolutionarily
conserved enzymatic mammalian target of rapamycin com-
plex 1 (mTORC1). In turn, if mTOR activity is inhibited by
rapamycin, the autophagy pathway is switched on. Rapa-
mycin exerts its stimulatory effect on autophagy by prevent-
ing mTOR phosphorylation at Ser-2448 and thereby
subsequently blocks mTOR signaling [64]. So far, many
different autophagic systems have been described including
macroautophagy and CMA that form the main pathways.
Macroautophagy is a multi-step process by which cytosolic
material is sequestered into a double-layered membrane
structure, the autophagosome, and is delivered to the lyso-
some for degradation. It is a highly orchestrated process and
involves autophagy-related (ATG) proteins. More than 30
genes have been identified in genetic analyses of yeast
mutants which have defects in autophagic function [65].
After autophagy stimulation through mTOR inhibition, the
formation of phagophores (autophagosome precursors/pre-
autophagosomal structures) is initiated in a not yet com-
pletely understood mechanism. A subset of ATG proteins is
required for autophagosome formation: First, the ATG9
system including ATG9, the ATG1 kinase complex (ATG1
and ATG13), ATG2 and ATG18; second, the phosphatidy-
linositol 3-OH kinase (PI(3)K) complex consisting of vacu-
olar protein sorting (VPS)34, VPS15, BECLIN 1/ATG6 and
ATG14 and third, the ubiquitin-like protein (Ubl) system
composed of two Ubl proteins (LC3/ATG8 and ATG12), an
E1 enzyme (ATG7), two analogues of E2 ubiquitin-
conjugating enzymes (ATG10 and ATG3), an LC3/ATG8-
modifying protease (ATG4), the protein target of ATG12
attachment (ATG5) and ATG16 [66]. BECLIN 1/ATG6
regulates autophagic trafficking and membrane trafficking
in a variety of physiological and pathological processes
[67]. Microtubule-associated protein 1 light chain 3 (LC3/
ATG8) is commonly used as a marker for autophagic activ-
ity. With its E1-like activity, ATG7 converts cytosolic LC3-I
to the membrane-associated LC3-II, which then is conjugat-
ed to phosphatidylethanolamine. LC3-II binds the inner and
outer membrane of the forming autophagosome and pro-
vides a physical link between the autophagosome and LC3
interacting proteins, such as Sequestosome 1 (p62/
SQSTM1) or Neighbor of brca1 gene 1 (NBR1). These so-
called autophagy receptors can simultaneously bind to ubiq-
uitinated proteins and LC3, employing their LC3-interacting
motif and ubiquitin-associated domain. The identification of
autophagy receptors, such as p62/SQSTM1 and NBR1 has
provided a molecular link between ubiquitination and
autophagy. Thus, p62/SQSTM1 and NBR1 are possibly also
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important bridging factors between UPS and autophagy
[68]. Through self-oligomerization, which is stimulated by
ubiquitin binding, p62/SQSTM1 sequesters ubiquitinated
substrates in form of inclusion bodies. These inclusions are
then specifically engulfed by the autophagosome membrane
by recruiting LC3 [69, 70].
While macroautophagy is considered as a rather unspe-
cific robust degradation process, CMA is a highly selective
lysosomal pathway that removes a distinct subset of proteins
containing a pentapeptide lysosome-targeting motif. These
substrates can on the one hand directly be translocated into
the lysosome after docking to the lysosomal receptor
lysosomal-associated membrane protein 2A or on the other
hand unfolded by a chaperone complex containing HSC70
and the co-chaperones BAG1, HIP, HSP70–HSP90 organiz-
ing protein (HOP) and HSP40/DNAJB1 [19]. These co-
chaperones provide a direct link to the UPS and the folding
and refolding activity of molecular chaperones. In the
course of aging, a variety of proteins tend to aggregate and
impair the UPS directly [71]. Therefore, these proteins, most
of which are ubiquitinated, cannot be handled by the pro-
teasome and have to be degraded by different protein clear-
ance pathways. Recently, it has been shown that the cellular
protein quality control (PQC) of polyubiquitinated proteins
by proteasomal and autophagic systems is regulated by the
HSP70 co-chaperones BAG1 and BAG3, respectively [40].
Proteasome activity decreases in an age-dependent manner
in a cell model of replicative senescent human fibroblasts
and is associated with an increased autophagic activity in
aged cells. This correlates with decreased levels of BAG1
and increased levels of BAG3 in aged cells, an age-related
BAG1/BAG3 switch that serves as an induction control of
the macroautophagic pathway (BAG3-mediated selective
macroautophagy) and may be considered as a backup of
the UPS in PQC ([40, 72]). Therefore, the expression shift
from BAG1 to BAG3 during aging, but also upon acute
stress (e.g. proteasome inhibition, oxidative stress), can be
considered as a physiologically important adaptive response
[20, 40]. The BAG3-mediated selective pathways have been
shown to be involved in a variety of disease causing pro-
cesses. In a model for HD, BAG3 in concert with HSPB8
facilitates the disposal of polyQ43-Huntingtin by stimulat-
ing macroautophagy and this complex is also involved in
Z-disc maintenance in flies, mice and men [73, 74]. Addi-
tionally, the transport of target proteins to the aggresome, a
compartment with high autophagic activity, has been shown
to be mediated by BAG3. This aggresome-targeting path-
way involving BAG3 and HSP70 is distinct from other
before-described mechanisms as it does not depend on sub-
strate ubiquitination [75].
Taken together the molecular chaperone machinery, the
UPS and the autophagy system are involved in PQC and
maintaining proteostasis within aging and disease to prevent
protein misfolding and aggregation. A summary of the main
routes for protein degradation is shown in Fig. 1. As aggre-
gated proteins are found in AD patients and aging is a
prevailing risk factor for AD it is important to further
characterize how these pathways are regulated and how
misregulation possibly contributes to the pathology of AD.
Proteostasis and AD
AD is characterized by the accumulation of intracellular Aβ
(oligomers), extracellular high molecular weight deposits of
Aβ peptides (fibrilliar forms), and the intracellular aggrega-
tion of hyper-phosphorylated Tau. Indeed, modification of
the cellular proteostasis and the metabolism of Aβ and Tau
have been proven to cause neuronal dysfunction and cell
death [12]. The malfunctioning proteostasis control results
in the accumulation of misfolded and aggregated proteins,
which is a general hallmark of aging and neurodegeneration,
as observed in PD, HD, ALS and AD. Aging in particular is
characterized by decreasing proteostasis capacity and in-
creasing protein damage which are in combination a major
challenge for the cell due to the inability to maintain meta-
stable proteins in folded states [76]. To counteract a cascade
of protein destabilization caused by metastable proteins
which escaped the PQC the proteostasis network including
molecular chaperones, the UPS and autophagic pathways
must manage the increasing burden of protein misfolding to
maintain proteome stability [77]. Since aging is the major
risk factor of AD [78–80], the age-dependent loss of proteo-
stasis might be an important contributor to the pathology of
AD. An overview of proteins that affect proteostasis in AD
is shown in Table 1.
Chaperones and AD
The two main chaperone scaffolds are HSP70 and HSP90
which are accompanied by a variety of co-chaperones spec-
ifying substrate binding and release and are transcriptionally
regulated through heat shock elements (HSE) via the tran-
scription factor HSF1. Interestingly, promoter studies of the
app gene showed HSEs within its promoter region suggest-
ing an impact of HSPs on AD pathology [81, 82]. As APP is
a membrane-associated protein it maturates in the endoplas-
mic reticulum (ER) and the Golgi apparatus [83]. There, the
ectodomain of APP associates with the luminal localized ER
chaperone glucose-related protein 78 (GRP78, the ER iso-
form of HSP70) and this interaction impairs its maturation
resulting in a reduced generation of Aβ40 and Aβ42 [84,
85]. The cytosolic HSP70 co-chaperone CHIP interacts with
intracellular domain of APP in the ER and Golgi compart-
ments providing a link between molecular chaperones and
the UPS in APP processing [86]. In addition to the ER and
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Golgi-associated HSPs, the cytosolic chaperones are as well
linked to APP and the Aβ metabolism [87]. The sHSPs
HSP22 and HSP27 have been shown to bind to fibrillar
Aβ to inhibit further fibrillarization. Moreover, HSP70 and
Fig. 1 The ubiquitin–proteasome system (UPS) and various autophagy routes as the main pathways for protein degradation (regular turnover) and
of misfolded and aggregated proteins (and mitochondria)
Table 1 Proteins affecting proteostasis in Alzheimer’s disease
Protein Function Reference
Aβ40/42 Decreases proteasome activity, modulates autophagy through mTOR signaling [99–102, 104, 143–146]
Tau Inhibitory effect of Tau aggregates on proteasome activity [115]
HSF1 Induces APP gene during stress [81, 82]
GRP78 (ER isoform
of HSP70)
Modulates APP maturation and reduces Aβ40/42 secretion [84, 85]
HSPs (HSP22, 27,
70, 90)
Small HSPs (HSP22, HSP27) bind to fibrillar amyloid plaques and inhibit their
fibrillarisation; HSP70, HSP90 inhibit early stages of amyloid aggregation
[88, 89]
CHIP E3 enzyme for phosphorylated Tau [93, 117]
BAG1 Regulates proteasomal degradation of Tau together with HSP70 [97]
PS1 Increases production of Aβ42, essential for lysosomal proteolysis and autophagy
by enabling the acidification of lysosomes required for protease activation
[163, 165]
UBB+1 Potently inhibits the degradation of polyubiquitinated substrates and therefore
induces neuronal cell death
[120, 121]
UCH-L1 DUB needed for proteasomal degradation of client proteins, oxidized and down-regulated in AD [124, 125]
UBQLN1 UBQLN1 activity is necessary to regulate the production of APP and APP fragments [127, 128]
mTOR Inhibitory and/or activating modulation of mTOR through Aβ42 but not Aβ40 [143–146]
BECLIN1 BECLIN1 is down-regulated in AD brains and consequently increases APP levels and
its metabolites
[161, 162]
Aβ amyloid beta, APP amyloid precursor protein, HSF1 heat shock transcription factor 1, GRP78 glucose-related protein 78, HSP heat shock
protein, CHIP carboxy terminus of HSC70-interacting protein, BAG1 BCL2-associated athanogene 1, PS1 Presenilin 1, UCH-L1 ubiquitin carboxy
terminal hydrolase isozyme 1, UBQLN1 Ubiquilin 1, mTOR mammalian target of rapamycin, DUB deubiquitination enzyme, ER endoplasmic
reticulum
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HSP90 inhibit early stages of Aβ aggregation [88, 89].
HSPs have also been associated with extracellular Aβ as
they can be released by either active secretion mechanisms
or from cells undergoing necrosis [90, 91]. In AD brains,
HSP90 co-localizes with amyloid plaques. Furthermore,
extracellular HSP90 and HSP70 increased the amount of
Aβ42 peptides in microglia after 1 day and decreased the
amount after 3 days in vitro. These observations suggest that
HSP-inducedmicroglial activationmay have a neuroprotective
role by facilitating Aβ clearance [90].
Besides extracellular Aβ accumulation, the second major
hallmark of AD is the intracellular aggregation of Tau. Post-
t rans la t ional modif ica t ions of Tau, e .g . hyper-
phosphorylation, affect the conformation of the protein and
promote the aggregation state. These post-translational
modifications impact the interaction of Tau with microtu-
bules, and thus, there may be specific forms of Tau that are
preferred chaperone substrates relative to others. HSP27,
HSP70 and CHIP are reported to recognize abnormal Tau
and reduce its concentration by assisting its degradation and
dephosphorylation [92–94]. HSP27 preferentially binds to
hyper-phosphorylated but not to non-phosphorylated Tau
and is cross-linked with Tau in NFTs from AD brains [94,
95]. Protein levels of soluble Tau positively correlate with
HSP27, HSP40, HSP90, alphaB-crystallin and CHIP levels
in AD brains [96]. Vice versa HSP protein levels are in-
versely correlated with levels of Tau oligomers, which are
an intermediate of Tau filaments. In different cellular mod-
els, it has been shown that increased HSP70 and HSP90
levels promote Tau solubility and microtubule binding [92].
Tau seems to directly bind to HSP70 and this interaction is
mediated by the HSP70 co-chaperone BAG1 pointing to a
tight interplay between molecular chaperones and the UPS
in counteracting Tau aggregation [97, 98]. Collectively,
these data suggest that up-regulation of molecular chaper-
ones may suppress formation of NTFs by partitioning Tau
into a productive folding pathway and thereby preventing
Tau aggregation.
Ubiquitin–Proteasome System and AD
The ubiquitin–proteasome system is the main degradation
pathway in the cell and it has been shown that Aβ40 and
Aβ42 can block proteasome function in vitro. Aβ40 binds
to the inner surface of proteasomes and inhibits 20S
chymotrypsin-like activity. Aβ42 can inhibit proteasome
function to an extent that is comparable to a well-known
proteasome inhibitor [99–102]. It still has to be elucidated
which form of Aβ is now affecting proteasome function.
There is experimental evidence that Aβ oligomers but not
monomers or fibrils impair long-term potentiation in vivo
[103]. In a cell free proteasome activity assay, it has been
shown that indeed Aβ40 and Aβ42 oligomers, but not
monomers, decreased proteolytic activity of the proteasome
in a dose-dependent manner [104]. The accumulation of
Aβ is dependent on the balance between Aβ production
and degradation. There is evidence suggesting that Aβ is
degraded by the proteasome because inhibition of the pro-
teasome with lactacystin caused a significant increase in
Aβ42 levels in cultured neurons and astrocytes [101]. Con-
sistent with these results, it has been shown that the 20S
proteasome degrades Aβ40 and Aβ42 in vitro and that
inhibition of the proteasome in cultured cells increases in-
tracellular Aβ40 and Aβ42 level [104]. So far, it is still a
matter of debate how the cytoplasmic and nuclear localized
proteasome could physically interact with extracellular or
luminal localized Aβ in vivo. In cultured neurons, it has
been shown via immunoelectron microscopy that 20S pro-
teasome subunits are detectable in the outer membranes and
inner vesicles of multivesicular bodies [105]. In normal and
AD brain, Aβ42 has also been shown to accumulate pre-
dominantly in multivesicular bodies, indicating that these
structures are the possible interaction site of Aβ and the
proteasome in vivo [106]. Further supporting the influence
of the UPS on Aβ metabolism, it has been shown that PS1
and PS2 are degraded via the proteasome. Thus, a decrease
in proteasome activity would increase γ-secretase activity
and thereby Aβ production [107]. This illustrates a clear
association between Aβ peptides and the proteostasis net-
work, highlighting the importance of chaperones and the
UPS in Aβ metabolism.
The protein Tau is degraded by the 26S and 20S protea-
some in vitro and the use of proteasome inhibitors in cells
and animal models leads to an accumulation of Tau
[108–111]. Furthermore, mass spectrometry studies on iso-
lated Tau from inclusion bodies show K48 and K63 ubiq-
uitin linkages on Tau, which are the recognition signals for
degradation via the UPS [112–114]. It has also been shown
that the 20S proteasome co-precipitated with Tau aggregates
and that the amount of pulled down Tau aggregates was
higher in samples with low proteasome activity, suggesting
an inhibitory interaction between Tau aggregates and pro-
teasome activity [115]. In addition, in vitro studies show that
Tau aggregates isolated from human AD brain directly in-
hibit the proteasome. In contrast, non-aggregated Tau iso-
lated from AD brain or from control brain did not interfere
with proteasome activity. These data show that different
aggregation states of Tau modify its turnover via the pro-
teasome [115]. Particularly intriguing is the aforementioned
ubiquitination of Tau. It has been shown that Tau co-
immunoprecipitates with CHIP, an E3 ubiquitin ligase, that
ubiquitinates Tau for subsequent degradation via the protea-
some and soluble phosphorylated Tau accumulates in brains
of CHIP knockout mice [93, 116, 117]. In AD, the mecha-
nism of stabilization and accumulation of hyper-
phosphorylated Tau may involve inhibition of Tau
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interaction with CHIP [116]. In addition to phosphorylation,
Tau is also post-translationally acetylated and this acetyla-
tion impairs proteosomal degradation and enhances accu-
mulation of Tau [118]. Moreover, changes in the
combination of proteasome subunits have been reported in
AD brain, resulting in an altered proteasome activity [119].
Taken together, these data clearly indicate that proteasome
activity is necessary for Tau turnover and that aggregated
Tau inhibits proteasomal function.
Ubiquitin immunoreactivity accumulates in aggregates in
AD brains and it has also been shown that some of these
structures enclose ubiquitin-B mutant protein (UBB+1). Over-
expression of this mutant, which contains a C-terminal amino
acid extension, leads to an impairment of the proteasome and
induces neuronal cell death [120, 121]. Oxidative stress is one
factor that leads to protein damage and subsequently to protein
ubiquitination and degradation via the proteasome [50]. It is
interesting to note that the ubiquitin carboxy-terminal hydrolase
L1 (UCH-L1) is oxidized in AD patients and is down-regulated
in specific brain regions of early AD cases [122, 123]. UCH-L1
functions as a deubiquitination enzyme (DUB) that hydrolyses
ubiquitin from polyubiquitinated proteins to liberate and stabi-
lize ubiquitin monomers and it promotes proteasomal degrada-
tion. Interestingly, when overexpressed, UCH-L1 reverses
behavioral deficits in AD model mice consistent with an im-
pairment of the UPS in AD [124, 125]. Several lines of evi-
dence implicate a tight regulation of the UPS and a strong
interaction with autophagic pathways to maintain proteostasis.
For example, Tau seems to be a substrate of the UPS and of the
autophagic system in vivo. Recently, it has been shown that
truncated Tau (TauΔc) is rapidly degraded via the autophagic
system whereas non-truncated Tau is favorably degraded via
the UPS [126]. In addition, Tau gets targeted for degradation
through HSP70 regardless of its phosphorylation state involv-
ing the molecular chaperone machinery, which in turn interacts
with the UPS-related proteins BAG1 and CHIP, both known to
be involved in Tau degradation [97].
Taken together, these data indicate that decreased UPS
function may be involved (or even partially causative) for
AD pathogenesis. This view is further strengthened by recent
genetic evidence showing a positive association between AD
and several single nucleotide polymorphisms in an ubiquitin-
like protein called ubiquilin 1 (UBQLN1). UBQLN1 is capa-
ble of preventing the aggregation of APP both in vitro and in
vivo [127, 128]. Interestingly, mutations in another member of
the ubiquilin family, ubiquilin 2 (UBQL2), are associated with
the motor neuron disease ALS, which supports a general role
of the UPS in neurodegeneration [129].
Autophagy and AD
Emerging evidence suggests a contribution of autophagic
pathways to AD pathogenesis. In fact, already in 1967
Suzuki and Terry reported dystrophic neurite swellings
filled with vacuolar structures positive for acid phosphatase
[130]. These structures have been shown to be unique for
AD and ultrastructural imaging of AD brains revealed that
they consist of lysosomes and a bulk of autophagic vacuoles
(AVs) [131, 132]. These histological changes reflect either
an increased synthesis of components of the lysosomal
system, a disturbed clearance of AVs, or both, as the accu-
mulation of vesicles can be initiated by blocking lysosomal
activity in primary neuronal cell lines [133–135]. A general
disturbance of neurite transport mechanism is not causative
for the accumulation of AVs as the transport of organelles
such as mitochondria appears unaltered under conditions of
lysosomal inhibition [135]. Neuronal tissue might be ex-
traordinarily susceptible for disturbances within the
autophagic-lysosomal system, because this network enables
neurons to perform highly specific functions such as vesicle
release and synaptic transmission [136]. Furthermore, post-
mitotic neurons have to cope with elevated levels of stress
and damaged organelles as well as misfolded or aggregated
proteins during their lifetime, cellular aging and disease
progression, which highlight the importance of an effective
degradation system in this particular cell type [137].
Besides changes of the autophagic system on a histological
level, also molecular regulators of autophagic degradation are
altered during AD progression. Genes that represent negative
regulators of autophagy are repressed, whereas positive mod-
ulators are more likely to be up-regulated in the brain of AD
patients [138]. However, enhanced expression of autophagy
activators does not result in a persistent increase of autophagic
activity as the autophagic efficacy declines during the course
of the disease, resulting in an accumulation of undegraded
proteins [139]. A key regulator of autophagic activity is
mTOR. The most prominent physiological modulator of
mTOR signaling is caloric restriction (CR) meaning the ener-
gy content of food is reduced without compromising the
supply of essential nutrients. CR represses mTOR signaling
and therefore enhances autophagic activity [140]. Attenuation
of AD as well as a prolonged lifespan in healthy humans
mediated by CR might not only be due to reduced metabolic
toxicity and decreased vulnerability to metabolic diseases like
diabetes, but may also rely on cytoprotective effects of
mTOR-mediated autophagic activity [141, 142]. Interestingly,
Aβ42, but not Aβ40, affects mTOR signaling and is as well
affected by mTOR modulation itself. The discussion, if Aβ
silences or enhances mTOR signaling is still ongoing: some
studies show inhibitory effects of Aβ on mTOR signaling,
while others show an activation [143–146]. In a murine neu-
roblastoma cell line (N2a) and hippocampal slice cultures
exposed to Aβ42, in APPswe/PS1, a double-transgenic
mouse model for AD, and in lymphocytes of AD patients,
the phosphorylation of mTOR as well as the phosphorylation
of its substrate p70S6-kinase is reduced [144, 145].
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Furthermore, in the Tg2576 APP-overexpressing mice, the
Aβ-mediated reduction of mTOR signaling has been shown
to be accompanied by a decline in synaptic activity that can be
rescued by mTOR up-regulation [145]. In contrast, cells
which produce high levels of Aβ oligomers show an en-
hanced mTOR activity which can be counteracted by decreas-
ing Aβ formation or administration of rapamycin. Similar
results have been seen in triple transgenic AD mice (3×Tg-
AD mice), combining Aβ and Tau-pathology of AD, which
show a reduction in Tau phosphorylation and improved learn-
ing and memory after rapamycin treatment. Interestingly, the
effects on mTOR signaling are only observed in brain areas
such as hippocampus and cortex which are also affected in
brains of AD patients, but not in others [143]. The beneficial
effect of rapamycin treatment and, therefore, autophagy stim-
ulation on learning and memory is also reported for a further
AD mouse model. These animals show a recovery of the
autophagic flux by enhanced autophagic activity in the hip-
pocampus after administration of rapamycin [146].
Interestingly, already in 1992, Haass and colleagues
reported a lysosomal pathway that is involved in APP pro-
cessing and potentially responsible for the generation of
amyloid-bearing fragments in AD via the generation of an
extensive array of APP C-terminal fragments (APP-CTFs)
which are found in lysosomes [147]. Later, alterations in the
metabolism of APP have been shown in models for glyco-
sphingolipid storage disease, where a mTOR-independent
increase in the autophagic vacuole-associated protein LC3-
II occurs, indicating an impaired lysosomal flux. This sug-
gests an anti-amyloidogenic role of lysosomal proteolysis in
post-secretase APP-CTF catabolism, which does not direct-
ly involve macroautophagy [148]. The accumulation of
sphingolipids, which characterizes lysosomal lipid storage
disorders, has also been shown to decrease the lysosome-
dependent degradation of APP-CTFs and to stimulate γ-
secretase activity [149]. Thus, sphingolipids might trigger
increased generation of Aβ via impairment of the autopha-
gic lysosomal system and contribute to neurodegeneration
in sporadic AD [149]. Pharmacological enhancement of
autophagy or induction of autophagy via starvation greatly
decreased the levels of Aβ peptides and APP-CTFs in a γ-
secretase independent manner. Consequently, after inhibi-
tion of autophagy, a significant accumulation of Aβ pepti-
des and APP-CTFs has been observed [150]. The upcoming
data support the involvement of autophagy in the clearance
of Aβ and APP-CTFs.
The autophagy receptor p62/SQSTM1 shows a reduced
expression in AD patients, as well as in 3×Tg-AD-express-
ing mice [151]. This might be caused by oxidative stress and
subsequent DNA damage of the p62/sqstm1 promoter,
which leads to reduced p62/sqstm1 transcription [151,
152]. Because guanine is the nucleobase which is most
susceptible to oxidation, the p62/sqstm1 promoter is
exceptionally prone to oxidative stress, as it is rich of GC
regions [153, 154]. Interestingly, Tau is degraded via the
autophagic-lysosomal system, whereby Tau aggregates are
cleared via macroautophagy [155]. As Tau possesses two
putative CMA-targeting motifs, soluble Tau is most likely
degraded via CMA [155]. Hyper-phosphorylated Tau accu-
mulates in p62/sqstm1-knockout mice [156], indicating an
interplay of oxidative stress and the clearance of protein
aggregates in AD. Another important modulator of autopha-
gic activity is BECLIN 1 which is a hub-protein-forming
multiprotein complexes that possess different functions
according to their composition [157–160]. BECLIN 1 is
down-regulated in the brain of AD patients even in cases
of mild cognitive impairment. In addition, mutant APP-
overexpressing mice with a heterozygous deletion of
BECLIN 1 show enhanced microglial activation and an
accumulation of lysosomes [161]. Moreover, the knock-
down of BECLIN 1 in cultured cells increases the levels
of APP and its cleavage products which are accompanied by
impaired autophagic flux. However, the overexpression of
mutant APP has no effect on BECLIN 1 expression in cells
and mice [161, 162].
Recently, it has been shown that PS1 is important for a
normal autophagic-lysosomal function independent of Aβ
[163]. PS1 has been found to be important for the acidifica-
tion of the lysosomal compartment and thus to be crucial for
lysosomal proteolysis and autophagic function. In neurons
lacking PS1, the subunit V01A of the vacuolar ATPase is
not correctly delivered to the lysosomes and not properly
integrated into the lysosomal membrane. This subunit is
needed for correct function of the proton pump, which is
responsible for lysosomal acidification. γ-secretase lacking
PS1 is not able to sufficiently facilitate N-glycosylation of
the V01A subunit in the ER, which is crucial for efficient
transport to the lysosomes and assembly of the functional
proton pump. As a result, V01A is entrapped in the ER and
cells loose lysosomal function. In addition, an accumulation
of AVs is seen in PS1 hypomorphic mice and the pharma-
cological block of lysosomal acidification leads to similar
accumulation of lysosomes and AVs in primary neuronal
cell lines [163]. The first abnormalities of the lysosomal-
endosomal system occur prior to other hallmarks of the
disease such as amyloid deposits in the neocortex and per-
sist until massive impairments of the autophagic system
emerge in the later stages of the disease [164]. Taken to-
gether, all these findings suggest an important role for
autophagy in the pathogenesis of AD.
Outlook
There is quite some evidence that in AD, the proteostasis
network is impaired. Based on pathological analysis, AD
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mouse models, in vitro and cellular investigations a molec-
ular link between chaperones, the ubiquitin–proteasome
system, autophagy pathways and pathogenetic mechanisms
of AD can be suggested. Deregulation and changes of
chaperones and proteasome activity might have serious
implications for aging as well as for age-associated diseases.
Autophagy pathways are key mechanisms and of vital im-
portance for cellular function and, especially, for cell sur-
vival under adverse conditions. Consequently, an effect of
proteostasis control on neurodegeneration or, vice versa, of
neurodegeneration on proteostasis is reasonable. As with
other pathomechanisms that are investigated in the search
for the cause of AD, it is still open whether an impairment of
proteostasis is an upstream or downstream event during AD
onset and progression. Experimental approaches employing
mouse models clearly demonstrate that stabilization or in-
duction of proteostasis can be neuroprotective. Whether this
can be translated into the human condition and, most impor-
tantly, whether supporting proteome integrity can be a real
target for pharmacological intervention for the prevention
and treatment of AD is currently still open. Also, one has to
consider that, e.g. the stimulation of general autophagy may
in the long term lead to the stimulation of proliferation of
non-neuronal cells, eventually resulting in tumor formation.
Indeed, a permanent autophagy induction is known as one
cellular mechanism that promotes the escape of cells from
proliferation control. As beneficial it may be to support
autophagy in post-mitotic neurons that are confronted with
disturbed proteostasis and an impairment of proteasome
function, this stimulation should target specific autophagy
pathways, such as selective chaperone-mediated macroau-
tophagy involved in the degradation of disease-associated
protein aggregation. Although there are obviously still many
questions to be answered to understand the role of proteo-
stasis in AD (and also in other age-associated neurodegen-
erative disorders), it is a big step forward in AD research to
consider a possible role of pathogenetic pathways that are
not directly linked to the usual suspects Aβ and Tau. A
better understanding of how the proteostasis network is
regulated might help to identify targets which lead to pre-
vention of the deleterious loss of neuronal cells and tissue
in AD.
Acknowledgements The authors wish to thank Michael Plenikowski
for artwork and Dr. Christine Ziegler for helpful input. This work was
supported by grants from the Alzheimer Forschung Initiative e.V. AFI
(to A.K.) and of the Deutsche Forschungsgemeinschaft (DFG FOR926
to C.B.).
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribution,
and reproduction in any medium, provided the original author(s) and
the source are credited.
References
1. Braak H, Braak E (1991) Neuropathological stageing of
Alzheimer-related changes. Acta Neuropathol 82:239–259
2. Kim J, Basak JM, Holtzman DM (2009) The role of apolipoprotein
E in Alzheimer’s disease. Neuron 63:287–303
3. Bertram L, Lill CM, Tanzi RE (2010) The genetics of Alzheimer
disease: back to the future. Neuron 68:270–281
4. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell
PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1993)
Science 261:921–923
5. Corder EH, Saunder AM, Risch NJ, Strittmatter WJ, Schmechel
DE, Gaskell PC, Rimmler JB, Locke PA, Conneally PM,
Schmader KE, Small GW, Roses AD, Haines JL, Pericak-Vance
MA (1994) Protective effect of apolipoprotein E type 2 allele for
late onset Alzheimer disease. Nat Genet 7:180–184
6. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M,
Enghild J, Salvesen GS, Roses AD (1993) Apolipoprotein E:
high-avidity binding to beta-amyloid and increased frequency of
type 4 allele in late-onset familial Alzheimer disease. Proc Natl
Acad Sci U S A 90:1977–1981
7. Selkoe DJ (2001) Alzheimer’s disease: genes, proteins, and therapy.
Physiol Rev 81:741–766
8. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s
disease: progress and problems on the road to therapeutics. Science
297:353–356
9. Crews L, Masliah E (2010) Molecular mechanisms of neurodegen-
eration in Alzheimer’s disease. Hum Mol Genet 19:R12–R20
10. Josephs KA, Whitwell JL, Ahmed Z, Shiung MM, Weigand SD,
Knopman DS, Boeve BF, Parisi JE, Petersen RC, Dickson DW,
Jack CR Jr (2008) Beta-amyloid burden is not associated with
rates of brain atrophy. Ann Neurol 63:204–212
11. Riley KP, Snowdon DA, Desrosiers MF, Markesbery WR (2005)
Early life linguistic ability, late life cognitive function, and neu-
ropathology: findings from the Nun Study. Neurobiol Aging
26:341–347
12. Ross CA, Poirier MA (2004) Protein aggregation and neurode-
generative disease. Nat Med 10(Suppl):S10–S17
13. Cohen E, Bieschke J, Perciavalle RM, Kelly JW, Dillin A (2006)
Opposing activities protect against age-onset proteotoxicity. Sci-
ence 313:1604–1610
14. Cohen E, Paulsson JF, Blinder P, Burstyn-Cohen T, Du D, Estepa
G, Adame A, Pham HM, Holzenberger M, Kelly JW, Masliah E,
Dillin A (2009) Reduced IGF-1 signaling delays age-associated
proteotoxicity in mice. Cell 139:1157–1169
15. Hartl FU, Bracher A, Hayer-Hartl M (2011) Molecular chaperones
in protein folding and proteostasis. Nature 475:324–332
16. Wilkinson KD, Urban MK, Haas AL (1980) Ubiquitin is the
ATP-dependent proteolysis factor I of rabbit reticulocytes. J Biol
Chem 255:7529–7532
17. Jariel-Encontre I, Bossis G, Piechaczyk M (2008) Ubiquitin-
independent degradation of proteins by the proteasome. Biochim
Biophys Acta 1786:153–177
18. Yang Z, Klionsky DJ (2010) Mammalian autophagy: core mo-
lecular machinery and signaling regulation. Curr Opin Cell Biol
22:124–131
19. Arias E, Cuervo AM (2011) Chaperone-mediated autophagy in
protein quality control. Curr Opin Cell Biol 23:184–189
20. Gamerdinger M, Carra S, Behl C (2011) Emerging roles of
molecular chaperones and co-chaperones in selective autophagy:
focus on BAG proteins. J Mol Med (Berl) 89:1175–1182
21. David DC, Ollikainen N, Trinidad JC, Cary MP, Burlingame AL,
Kenyon C (2010) Widespread protein aggregation as an inherent
part of aging in C. elegans. PLoS Biol 8:e1000450
50 Mol Neurobiol (2012) 46:41–54
22. Demontis F, Perrimon N (2010) FOXO/4E-BP signaling in Dro-
sophila muscles regulates organism-wide proteostasis during ag-
ing. Cell 143:813–825
23. Chen B, Retzlaff M, Roos T, Frydman J (2011) Cellular strategies of
protein quality control. Cold Spring Harb Perspect Biol 3:a004374
24. Dobson CM (2003) Protein folding and misfolding. Nature
426:884–890
25. Hartl FU (1996) Molecular chaperones in cellular protein folding.
Nature 381:571–579
26. Hartl FU, Hayer-Hartl M (2009) Converging concepts of protein
folding in vitro and in vivo. Nat Struct Mol Biol 16:574–581
27. Richter K, Haslbeck M, Buchner J (2010) The heat shock re-
sponse: life on the verge of death. Mol Cell 40:253–266
28. Powers ET, Morimoto RI, Dillin A, Kelly JW, Balch WE (2009)
Biological and chemical approaches to disease of proteostasis
deficiency. Annu Rev Biochem 78:959–991
29. Arndt V, Rogon C, Höhfeld J (2007) To be or not to be—
molecular chaperones in protein degradation. Cell Mol Life Sci
64:2525–2541
30. Balch WE, Morimoto RI, Dillin A, Kelly JW (2008) Adapting
proteostasis for disease intervention. Science 319:916–919
31. Bukau B, Horwich AL (1998) The Hsp70 and Hsp60 chaperone
machines. Cell 92:351–366
32. Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM
(2002) Chaperone suppression of alpha-synuclein toxicity in a
Drosophila model for Parkinson’s disease. Science 295:865–868
33. Cummings CJ, Sun Y, Opal P, Antalffy B, Mestril R, Orr HT,
Dillmann WH, Zoghbi HY (2001) Over-expression of inducible
HSP70 chaperone suppresses neuropathology and improves motor
function in SCA1 mice. Hum Mol Genet 10:1511–1518
34. Kampinga HH, Craig EA (2010) The HSP70 chaperone machin-
ery: J proteins as drivers of functional specificity. Nat Rev Mol
Cell Biol 11:579–592
35. Mayer MP (2010) Gymnastics of molecular chaperones. Mol Cell
39:321–331
36. Westhoff B, Chapple JP, van der Spuy J, Hohfeld J, Cheetham
ME (2005) HSJ1 is a neuronal shuttling factor for the sorting of
chaperone clients to the proteasome. Curr Biol 15:1058–1064
37. Nollen EA, Kabakov AE, Brunsting JF, Kanon B, Hohfeld J,
Kampinga HH (2001) Modulation of in vivo HSP70 chaperone
activity by Hip and Bag-1. J Biol Chem 276:4677–4682
38. Hartl FU, Hayer-Hartl M (2002) Molecular chaperones in the
cytosol: from nascent chain to folded protein. Science 295:1852–
1858
39. Tsai YC, Fishman PS, Thakor NV, Oyler GA (2003) Parkin
facilitates the elimination of expanded polyglutamine proteins
and leads to preservation of proteasome function. J Biol Chem
278:22044–22055
40. Gamerdinger M, Hajieva P, Kaya AM, Wolfrum U, Hartl FU,
Behl C (2009) Protein quality control during aging involves
recruitment of the macroautophagy pathway by BAG3. EMBO
J 28:889–901
41. Morimoto RI (2008) Proteotoxic stress and inducible chaperone
networks in neurodegenerative disease and aging. Genes Dev
22:1427–1438
42. Kern A, Ackermann B, Clement AM, Duerk H, Behl C (2010)
HSF1-controlled and age-associated chaperone capacity in neu-
rons and muscle cells of C. elegans. PLoS One 5:e8568
43. Tatar M, Khazaeli AA, Curtsinger JW (1997) Chaperoning ex-
tended life. Nature 390:30
44. Wu D, Cypser JR, Yashin AI, Johnson TE (2009) Multiple mild
heat-shocks decrease the Gompertz component of mortality in
Caenorhabditis elegans. Exp Gerontol 44:607–612
45. Yokoyama K, Fukumoto K, Murakami T, Harada S, Hosono R,
Wadhwa R, Mitsui Y, Ohkuma S (2002) Extended longevity of
Caenorhabditis elegans by knocking in extra copies of hsp70F, a
homolog of mot-2 (mortalin)/mthsp70/Grp75. FEBS Lett 516:53–57
46. Heydari AR, You S, Takahashi R, Gutsmann-Conrad A, Sarge
KD, Richardson A (2000) Age-related alterations in the activa-
tion of heat shock transcription factor 1 in rat hepatocytes. Exp
Cell Res 256:83–93
47. Garigan D, Hsu AL, Fraser AG, Kamath RS, Ahringer J, Kenyon
C (2002) Genetic analysis of tissue aging in Caenorhabditis
elegans: a role for heat-shock factor and bacterial proliferation.
Genetics 161:1101–1112
48. Hsu AL, Murphy CT, Kenyon C (2003) Regulation of aging and
age-related disease by DAF-16 and heat-shock factor. Science
300:1142–1145
49. Murphy MP (2009) How mitochondria produce reactive oxygen
species. Biochem J 417:1–13
50. Shang F, Taylor A (2011) Ubiquitin–proteasome pathway and
cellular responses to oxidative stress. Free Radic Biol Med
51:5–16
51. Jung T, Catalgol B, Grune T (2009) The proteasomal system. Mol
Aspects Med 30:191–296
52. Kopito RR (2000) Aggresomes, inclusion bodies and protein
aggregation. Trends Cell Biol 10:524–530
53. Chen Z, Pickart CM (1990) A 25-kilodalton ubiquitin carrier
protein (E2) catalyzes multi-ubiquitin chain synthesis via lysine
48 of ubiquitin. J Biol Chem 265:21835–21842
54. Haas AL, Siepmann TJ (1997) Pathways of ubiquitin conjugation.
FASEB J 11:1257–1268
55. Komander D (2009) The emergingcomplexity of protein ubiqui-
tination. Biochem Soc Trans 37:937–953
56. Deribe YL, Pawson T, Dikic I (2010) Post-translational modifi-
cations in signal integration. Nat Struct Mol Biol 17:666–672
57. Haglund K, Dikic I (2005) Ubiquitination and cell signaling.
EMBO J 24:3353–3359
58. Hicke L, Dunn R (2003) Regulation of membrane protein transport
by ubiquitin and ubiquitin-binding proteins. Annu Rev Cell Dev
Biol 19:141–172
59. Ikeda F, Dikic I (2008) Atypical ubiquitin chains: new molecular
signals. ‘Protein modifications: beyond the usual suspects’ re-
view series. EMBO Rep 9:536–542
60. Zouambia M, Fischer DF, Hobo B, De Vos RA, Hol EM, Varndell
IM, Sheppard PW, Van Leeuwen FW (2008) Proteasome subunit
proteins and neuropathology in tauopathies and synucleinopa-
thies: consequences for proteomic analyses. Proteomics 8:1221–
1236
61. Bedford L, Hay D, Paine S, Rezvani N, Mee M, Lowe J, Mayer
RJ (2008) Is malfunction of the ubiquitin proteasome system the
primary cause of alpha-synucleinopathies and other chronic hu-
man neurodegenerative disease? Biochim Biophys Acta 1782:683–
690
62. Gray DA, Tsirigotis M, Woulfe J (2003) Ubiquitin, proteasomes,
and the aging brain. Sci Aging Knowl Environ 2003:RE6
63. Li XJ, Li S (2011) Proteasomal dysfunction in aging and
Huntington disease. Neurobiol Dis 43:4–8
64. Chiang GG, Abraham RT (2005) Phosphorylation of mammalian
target of rapamycin (mTOR) at Ser-2448 is mediated by p70S6
kinase. J Biol Chem 280:25485–25490
65. Suzuki K, Ohsumi Y (2007) Molecular machinery of autophago-
some formation in yeast, Saccharomyces cerevisiae. FEBS Lett
581:2156–2161
66. Xie Z, Klionsky DJ (2007) Autophagosome formation: core
machinery and adaptations. Nat Cell Biol 9:1102–1109
67. Kang R, Zeh HJ, Lotze MT, Tang D (2011) The Beclin 1 network
regulates autophagy and apoptosis. Cell Death Differ 18:571–580
68. Kirkin V, McEwan DG, Novak I, Dikic I (2009) A role for
ubiquitin in selective autophagy. Mol Cell 34:259–269
Mol Neurobiol (2012) 46:41–54 51
69. Bjorkoy G, Lamark T, Brech A, Outzen H, Perander M, Overvatn
A, Stenmark H, Johansen T (2005) p62/SQSTM1 forms protein
aggregates degraded by autophagy and has a protective effect on
huntingtin-induced cell death. J Cell Biol 171:603–614
70. Pankiv S, Clausen TH, Lamark T, Brech A, Bruun JA, Outzen H,
Overvatn A, Bjorkoy G, Johansen T (2007) p62/SQSTM1 binds
directly to Atg8/LC3 to facilitate degradation of ubiquitinated
protein aggregates by autophagy. J Biol Chem 282:24131–24145
71. Bence NF, Sampat RM, Kopito RR (2001) Impairment of the
ubiquitin–proteasome system by protein aggregation. Science
292:1552–1555
72. Behl C (2011) BAG3 and friends: co-chaperones in selective
autophagy during aging and disease. Autophagy 7:795–798
73. Arndt V, Dick N, Tawo R, Dreiseidler M, Wenzel D, Hesse M,
Furst DO, Saftig P, Saint R, Fleischmann BK, Hoch M, Hohfeld J
(2010) Chaperone-assisted selective autophagy is essential for
muscle maintenance. Curr Biol 20:143–148
74. Carra S, Seguin SJ, Lambert H, Landry J (2008) HspB8 chaper-
one activity toward poly(Q)-containing proteins depends on its
association with Bag3, a stimulator of macroautophagy. J Biol
Chem 283:1437–1444
75. Gamerdinger M, Kaya AM, Wolfrum U, Clement AM, Behl C
(2011) BAG3 mediates chaperone-based aggresome-targeting
and selective autophagy of misfolded proteins. EMBO Rep
12:149–156
76. Ben-Zvi A, Miller EA, Morimoto RI (2009) Collapse of proteo-
stasis represents an early molecular event in Caenorhabditis
elegans aging. Proc Natl Acad Sci U S A 106:14914–14919
77. Gidalevitz T, Ben-Zvi A, Ho KH, Brignull HR, Morimoto RI
(2006) Progressive disruption of cellular protein folding in models
of polyglutamine diseases. Science 311:1471–1474
78. Ball MJ (1982) Alzheimer’s disease: a challenging enigma. Arch
Pathol Lab Med 106(4):157–162
79. Price DL, Kitt CA, Struble RG, Whitehouse PJ, Cork LC, Walker
LC (1985) Neurobiological studies of transmitter systems in
aging and in Alzheimer-type dementia. Ann New York Acad
Sci 457:35–51
80. Kern A, Behl C (2009) The unsolved relationship of brain aging
and late-onset Alzheimer disease. Biochim Biophys Acta
1790:1124–1132
81. Dewji NN, Do C (1996) Heat shock factor-1 mediates the transcrip-
tional activation of Alzheimer’s beta-amyloid precursor protein
gene in response to stress. Brain Res Mol Brain Res 35:325–328
82. Salbaum JM, Weidemann A, Lemaire HG, Masters CL, Beyreuther
K (1988) The promoter of Alzheimer’s disease amyloid A4 precursor
gene. EMBO J 7:2807–2813
83. Caporaso GL, Takei K, Gandy SE, Matteoli M, Mundigl O,
Greengard P, De Camilli P (1994) Morphologic and biochemical
analysis of the intracellular trafficking of the Alzheimer beta/A4
amyloid precursor protein. J Neurosci 14:3122–3138
84. Hoshino T, Nakaya T, Araki W, Suzuki K, Suzuki T, Mizushima
T (2007) Endoplasmic reticulum chaperones inhibit the production
of amyloid-beta peptides. Biochem J 402:581–589
85. Yang Y, Turner RS, Gaut JR (1998) The chaperone BiP/GRP78
binds to amyloid precursor protein and decreases Abeta40 and
Abeta42 secretion. J Biol Chem 273:25552–25555
86. Kumar P, Ambasta RK, Veereshwarayya V, Rosen KM,
Kosik KS, Band H, Mestril R, Patterson C, Querfurth HW
(2007) CHIP and HSPs interact with beta-APP in a
proteasome-dependent manner and influence Abeta metabo-
lism. Hum Mol Genet 16:848–864
87. Cottrell BA, Galvan V, Banwait S, Gorostiza O, Lombardo CR,
Williams T, Schilling B, Peel A, Gibson B, Koo EH, Link CD,
Bredesen DE (2005) A pilot proteomic study of amyloid precur-
sor interactors in Alzheimer’s disease. Ann Neurol 58:277–289
88. Evans CG, Wisen S, Gestwicki JE (2006) Heat shock proteins 70
and 90 inhibit early stages of amyloid beta-(1-42) aggregation in
vitro. J Biol Chem 281:33182–33191
89. Wilhelmus MM, Otte-Holler I, Wesseling P, de Waal RM, Boelens
WC, Verbeek MM (2006) Specific association of small heat shock
proteins with the pathological hallmarks of Alzheimer’s disease
brains. Neuropathol Appl Neurobiol 32:119–130
90. Kakimura J, Kitamura Y, Takata K, Umeki M, Suzuki S,
Shibagaki K, Taniguchi T, Nomura Y, Gebicke-Haerter PJ,
SmithMA, Perry G, Shimohama S (2002)Microglial activation and
amyloid-beta clearance induced by exogenous heat-shock proteins.
FASEB J 16:601–603
91. Calderwood SK, Mambula SS, Gray PJJR (2007) Extracellular
heat shock proteins in cell signal and immunity. Ann New York
Acad Sci 1113:29–39
92. Dou F, Netzer WJ, Tanemura K, Li F, Hartl FU, Takashima A,
Gouras GK, Greengard P, Xu H (2003) Chaperones increase
association of tau protein with microtubules. Proc Natl Acad
Sci U S A 100:721–726
93. Petrucelli L, Dickson D, Kehoe K, Taylor J, Snyder H, Grover A,
De LuciaM,McGowan E, Lewis J, Prihar G, Kim J, DillmannWH,
Browne SE, Hall A, Voellmy R, Tsuboi Y, Dawson TM,Wolozin B,
Hardy J, Hutton M (2004) CHIP and Hsp70 regulate tau ubiquiti-
nation, degradation and aggregation. Hum Mol Genet 13:703–714
94. Shimura H, Miura-Shimura Y, Kosik KS (2004) Binding of tau to
heat shock protein 27 leads to decreased concentration of hyper-
phosphorylated tau and enhanced cell survival. J Biol Chem
279:17957–17962
95. Nemes Z, Devreese B, Steinert PM, Van Beeumen J, Fesus L (2004)
Cross-linking of ubiquitin, HSP27, parkin, and alpha-synuclein by
gamma-glutamyl-epsilon-lysine bonds in Alzheimer’s neurofibrillary
tangles. FASEB J 18:1135–1137
96. Sahara N, Maeda S, Yoshiike Y, Mizoroki T, Yamashita S,
Murayama M, Park JM, Saito Y, Murayama S, Takashima A
(2007) Molecular chaperone-mediated tau protein metabolism
counteracts the formation of granular tau oligomers in human
brain. J Neurosci Res 85:3098–3108
97. Elliott E, Tsvetkov P, Ginzburg I (2007) BAG-1 associates with
Hsc70.Tau complex and regulates the proteasomal degradation of
Tau protein. J Biol Chem 282:37276–37284
98. Sarkar M, Kuret J, Lee G (2008) Two motifs within the tau
microtubule-binding domain mediate its association with the
hsc70 molecular chaperone. J Neurosci Res 86:2763–2773
99. Gregori L, Fuchs C, Figueiredo-Pereira ME, Van Nostrand WE,
Goldgaber D (1995) Amyloid beta-protein inhibits ubiquitin-
dependent protein degradation in vitro. J Biol Chem 270:19702–
19708
100. Gregori L, Hainfeld JF, Simon MN, Goldgaber D (1997) Binding of
amyloid beta protein to the 20 S proteasome. J Biol Chem 272:58–62
101. Lopez Salon M, Pasquini L, Besio Moreno M, Pasquini JM, Soto E
(2003) Relationship between beta-amyloid degradation and the 26S
proteasome in neural cells. Exp Neurol 180:131–143
102. Oh S, Hong HS, Hwang E, Sim HJ, Lee W, Shin SJ, Mook-Jung I
(2005) Amyloid peptide attenuates the proteasome activity in
neuronal cells. Mech Ageing Dev 126:1292–1299
103. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe
MS, Rowan MJ, Selkoe DJ (2002) Naturally secreted oligomers
of amyloid beta protein potently inhibit hippocampal long-term
potentiation in vivo. Nature 416:535–539
104. Tseng BP, Green KN, Chan JL, Blurton-Jones M, LaFerla FM
(2008) Abeta inhibits the proteasome and enhances amyloid and
tau accumulation. Neurobiol Aging 29:1607–1618
105. Almeida CG, Takahashi RH, Gouras GK (2006) Beta-amyloid
accumulation impairs multivesicular body sorting by inhibiting
the ubiquitin-proteasome system. J Neurosci 26:4277–4288
52 Mol Neurobiol (2012) 46:41–54
106. Takahashi RH, Milner TA, Li F, Nam EE, Edgar MA, Yamaguchi
H, Beal MF, Xu H, Greengard P, Gouras GK (2002) Intraneuronal
Alzheimer abeta42 accumulates in multivesicular bodies and is
associated with synaptic pathology. Am J Pathol 161:1869–1879
107. Checler F, da Costa CA, Ancolio K, Chevallier N, Lopez-Perez E,
Marambaud P (2000) Role of the proteasome in Alzheimer’s
disease. Biochim Biophys Acta 1502:133–138
108. Cardozo C, Michaud C (2002) Proteasome-mediated degradation
of tau proteins occurs independently of the chymotrypsin-like
activity by a nonprocessive pathway. Arch Biochem Biophys
408:103–110
109. David DC, Layfield R, Serpell L, Narain Y, Goedert M, Spillantini
MG (2002) Proteasomal degradation of tau protein. J Neurochem
83:176–185
110. Liu YH, Wei W, Yin J, Liu GP, Wang Q, Cao FY, Wang JZ (2009)
Proteasome inhibition increases tau accumulation independent of
phosphorylation. Neurobiol Aging 30:1949–1961
111. Ren QG, Liao XM,Wang ZF, Qu ZS,Wang JZ (2006) The involve-
ment of glycogen synthase kinase-3 and protein phosphatase-2A in
lactacystin-induced tau accumulation. FEBS Lett 580:2503–2511
112. Babu JR, Geetha T, Wooten MW (2005) Sequestosome 1/p62
shuttles polyubiquitinated tau for proteasomal degradation. J
Neurochem 94:192–203
113. Cripps D, Thomas SN, Jeng Y, Yang F, Davies P, Yang AJ (2006)
Alzheimer disease-specific conformation of hyperphosphorylated
paired helical filament-Tau is polyubiquitinated through Lys-48, Lys-
11, and Lys-6 ubiquitin conjugation. J Biol Chem 281:10825–10838
114. Seibenhener ML, Babu JR, Geetha T, Wong HC, Krishna NR,
Wooten MW (2004) Sequestosome 1/p62 is a polyubiquitin chain
binding protein involved in ubiquitin proteasome degradation.
Mol Cell Biol 24:8055–8068
115. Keck S, Nitsch R, Grune T, Ullrich O (2003) Proteasome inhibi-
tion by paired helical filament-tau in brains of patients with
Alzheimer’s disease. J Neurochem 85:115–122
116. Dickey CA, Yue M, Lin WL, Dickson DW, Dunmore JH, Lee
WC, Zehr C, West G, Cao S, Clark AM, Caldwell GA, Caldwell
KA, Eckman C, Patterson C, Hutton M, Petrucelli L (2006)
Deletion of the ubiquitin ligase CHIP leads to the accumulation,
but not the aggregation, of both endogenous phospho- and
caspase-3-cleaved tau species. J Neurosci 26:6985–6996
117. Shimura H, Schwartz D, Gygi SP, Kosik KS (2004) CHIP-Hsc70
complex ubiquitinates phosphorylated tau and enhances cell sur-
vival. J Biol Chem 279:4869–4876
118. Min SW, Cho SH, Zhou Y, Schroeder S, Haroutunian V, Seeley
WW, Huang EJ, Shen Y, Masliah E, Mukherjee C, Meyers D,
Cole PA, Ott M, Gan L (2010) Acetylation of tau inhibits its
degradation and contributes to tauopathy. Neuron 67:953–966
119. Mishto M, Bellavista E, Santoro A, Stolzing A, Ligorio C,
Nacmias B, Spazzafumo L, Chiappelli M, Licastro F, Sorbi
S, Pession A, Ohm T, Grune T, Franceschi C (2006) Immunopro-
teasome and LMP2 polymorphism in aged and Alzheimer’s disease
brains. Neurobiol Aging 27:54–66
120. LamYA, Pickart CM,Alban A, LandonM, Jamieson C, Ramage R,
Mayer RJ, Layfield R (2000) Inhibition of the ubiquitin–proteasome
system in Alzheimer’s disease. Proc Natl Acad Sci U S A 97:9902–
9906
121. Tan Z, Sun X, Hou FS, Oh HW, Hilgenberg LG, Hol EM, van
Leeuwen FW, Smith MA, O’Dowd DK, Schreiber SS (2007)
Mutant ubiquitin found in Alzheimer’s disease causes neuritic
beading of mitochondria in association with neuronal degeneration.
Cell Death Differ 14:1721–1732
122. Castegna A, Aksenov M, Aksenova M, Thongboonkerd V, Klein
JB, Pierce WM, Booze R, Markesbery WR, Butterfield DA
(2002) Proteomic identification of oxidatively modified proteins
in Alzheimer’s disease brain. Part I: creatine kinase BB, glutamine
synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic
Biol Med 33:562–571
123. Pasinetti GM (2001) Use of cDNA microarray in the search for
molecular markers involved in the onset of Alzheimer’s disease
dementia. J Neurosci Res 65:471–476
124. Gong B, Cao Z, Zheng P, Vitolo OV, Liu S, Staniszewski A,
Moolman D, Zhang H, Shelanski M, Arancio O (2006) Ubiquitin
hydrolase Uch-L1 rescues beta-amyloid-induced decreases in
synaptic function and contextual memory. Cell 126:775–788
125. Smith DL, Pozueta J, Gong B, Arancio O, Shelanski M (2009)
Reversal of long-term dendritic spine alterations in Alzheimer
disease models. Proc Natl Acad Sci U S A 106:16877–16882
126. Dolan PJ, Johnson GV (2010) A caspase cleaved form of tau is
preferentially degraded through the autophagy pathway. J Biol
Chem 285:21978–21987
127. Bertram L, Hiltunen M, Parkinson M, Ingelsson M, Lange C,
Ramasamy K,Mullin K, Menon R, Sampson AJ, Hsiao MY, Elliott
KJ, Velicelebi G, Moscarillo T, Hyman BT, Wagner SL, Becker
KD, Blacker D, Tanzi RE (2005) Family-based association between
Alzheimer’s disease and variants in UBQLN1. N Engl J Med
352:884–894
128. Stieren ES, El Ayadi A, Xiao Y, Siller E, Landsverk ML,
Oberhauser AF, Barral JM, Boehning D (2011) Ubiquilin-1
is a molecular chaperone for the amyloid precursor protein. J Biol
Chem 286:35689–35698
129. Deng HX, Chen W, Hong ST, Boycott KM, Gorrie GH, Siddique
N, Yang Y, Fecto F, Shi Y, Zhai H, Jiang H, Hirano M,
Rampersaud E, Jansen GH, Donkervoort S, Bigio EH, Brooks BR,
Ajroud K, Sufit RL, Haines JL, Mugnaini E, Pericak-Vance MA,
Siddique T (2011)Mutations in UBQLN2 cause dominant X-linked
juvenile and adult-onset ALS and ALS/dementia. Nature 477:211–
215
130. Suzuki K, Terry RD (1967) Fine structural localization of acid
phosphatase in senile plaques in Alzheimer’s presenile dementia.
Acta Neuropathol 8:276–284
131. Benzing WC, Mufson EJ, Armstrong DM (1993) Alzheimer’s
disease-like dystrophic neurites characteristically associated with
senile plaques are not found within other neurodegenerative dis-
eases unless amyloid beta-protein deposition is present. Brain Res
606:10–18
132. Nixon RA, Wegiel J, Kumar A, Yu WH, Peterhoff C, Cataldo A,
Cuervo AM (2005) Extensive involvement of autophagy in
Alzheimer disease: an immuno-electron microscopy study. J
Neuropathol Exp Neurol 64:113–122
133. Cataldo AM, Barnett JL, Berman SA, Li J, Quarless S, Bursztajn
S, Lippa C, Nixon RA (1995) Gene expression and cellular
content of cathepsin D in Alzheimer’s disease brain: evidence
for early up-regulation of the endosomal-lysosomal system. Neuron
14:671–680
134. Cataldo AM, Paskevich PA, Kominami E, Nixon RA (1991)
Lysosomal hydrolases of different classes are abnormally distrib-
uted in brains of patients with Alzheimer disease. Proc Natl Acad
Sci U S A 88:10998–11002
135. Lee S, Sato Y, Nixon RA (2011) Lysosomal proteolysis inhibition
selectively disrupts axonal transport of degradative organelles
and causes an Alzheimer’s-like axonal dystrophy. J Neurosci
31:7817–7830
136. Nixon RA, Yang DS, Lee JH (2008) Neurodegenerative lysosomal
disorders: a continuum from development to late age. Autophagy
4:590–599
137. Wong E, Cuervo AM (2010) Autophagy gone awry in neurode-
generative diseases. Nat Neurosci 13:805–811
138. Lipinski MM, Zheng B, Lu T, Yan Z, Py BF, Ng A, Xavier RJ, Li
C, Yankner BA, Scherzer CR, Yuan J (2010) Genome-wide
analysis reveals mechanisms modulating autophagy in normal
Mol Neurobiol (2012) 46:41–54 53
brain aging and in Alzheimer’s disease. Proc Natl Acad Sci U S A
107:14164–14169
139. Yu WH, Cuervo AM, Kumar A, Peterhoff CM, Schmidt SD, Lee
JH, Mohan PS, Mercken M, Farmery MR, Tjernberg LO, Jiang Y,
Duff K, Uchiyama Y, Naslund J, Mathews PM, Cataldo AM,
Nixon RA (2005) Macroautophagy—a novel Beta-amyloid
peptide-generating pathway activated in Alzheimer’s disease. J
Cell Biol 171:87–98
140. Powers RW 3rd, Kaeberlein M, Caldwell SD, Kennedy BK,
Fields S (2006) Extension of chronological life span in yeast by
decreased TOR pathway signaling. Genes Dev 20:174–184
141. Masoro EJ (2003) Subfield history: caloric restriction, slowing
aging, and extending life. Sci Aging Knowl Environ 2003:RE2
142. Pasinetti GM, Zhao Z, Qin W, Ho L, Shrishailam Y, Macgrogan
D, Ressmann W, Humala N, Liu X, Romero C, Stetka B,
Chen L, Ksiezak-Reding H, Wang J (2007) Caloric intake
and Alzheimer’s disease. Experimental approaches and therapeutic
implications. Interdiscip Top Gerontol 35:159–175
143. Caccamo A, Majumder S, Richardson A, Strong R, Oddo S
(2010) Molecular interplay between mammalian target of rapa-
mycin (mTOR), amyloid-beta, and Tau: effects on cognitive
impairments. J Biol Chem 285:13107–13120
144. Lafay-Chebassier C, Paccalin M, Page G, Barc-Pain S, Perault-
Pochat MC, Gil R, Pradier L, Hugon J (2005) mTOR/p70S6k
signalling alteration by Abeta exposure as well as in APP-PS1
transgenic models and in patients with Alzheimer’s disease. J
Neurochem 94:215–225
145. Ma T, Hoeffer CA, Capetillo-Zarate E, Yu F, Wong H, Lin MT,
Tampellini D, Klann E, Blitzer RD, Gouras GK (2010) Dysregu-
lation of the mTOR pathway mediates impairment of synaptic
plasticity in a mouse model of Alzheimer’s disease. PLoS One 5
(9):e12845. doi:10.1371/journal.pone.0012845
146. Spilman P, Podlutskaya N, Hart MJ, Debnath J, Gorostiza O,
Bredesen D, Richardson A, Strong R, Galvan V (2010) Inhibition
of mTOR by rapamycin abolishes cognitive deficits and reduces
amyloid-beta levels in a mouse model of Alzheimer’s disease.
PLoS One 5:e9979
147. Haass C, Koo EH, Mellon A, Hung AY, Selkoe DJ (1992)
Targeting of cell-surface β-amyloid precursor protein to lyso-
somes: alternative processing into amyloid-bearing fragments.
Nature 357:500–503
148. Boland B, Smith DA, Mooney D, Jung SS, Walsh DM, Platt FM
(2010) Macroautophagy is not directly involved in the metabolism
of amyloid precurser protein. J Biol Chem 285:37415–37426
149. Tamboli IY, Hampel H, Tien NT, Tolksdorf K, Breiden B, Mathews
PM, Saftig P, Sandhoff K, Walter J (2011) Sphingolipid storage
affects autophagic metabolism of the amyloid precursor protein and
promotes Aβ generation. J Neurosci 31:1837–1849
150. Tian Y, Bustos V, Flajolet M, Greengard P (2011) A small-molecule
enhancer of autophagy decreases levels of Abeta and APP-CTF via
Atg5-dependent autophagy pathway. FASEB J 25:1934–1942
151. Du Y, Wooten MC, Gearing M, Wooten MW (2009) Age-
associated oxidative damage to the p62 promoter: implications
for Alzheimer disease. Free Radic Biol Med 46:492–501
152. Du Y, Wooten MC, Wooten MW (2009) Oxidative damage to the
promoter region of SQSTM1/p62 is common to neurodegenerative
disease. Neurobiol Dis 35:302–310
153. Steenken S (1989) Structure, acid/base properties and transformation
reactions of purine radicals. Free Radic Res Commun 6:117–120
154. Vadlamudi RK, Shin J (1998) Genomic structure and promoter
analysis of the p62 gene encoding a non-proteasomal multiubiquitin
chain binding protein. FEBS Lett 435:138–142
155. Wang Y, Martinez-Vicente M, Kruger U, Kaushik S, Wong E,
Mandelkow EM, Cuervo AM, Mandelkow E (2009) Tau frag-
mentation, aggregation and clearance: the dual role of lysosomal
processing. Hum Mol Genet 18:4153–4170
156. Ramesh Babu J, Lamar Seibenhener M, Peng J, Strom AL,
Kemppainen R, Cox N, Zhu H, Wooten MC, Diaz-Meco MT,
Moscat J, Wooten MW (2008) Genetic inactivation of p62 leads
to accumulation of hyperphosphorylated tau and neurodegeneration.
J Neurochem 106:107–120
157. Fimia GM, Stoykova A, Romagnoli A, Giunta L, Di Bartolomeo
S, Nardacci R, Corazzari M, Fuoco C, Ucar A, Schwartz P, Gruss
P, Piacentini M, Chowdhury K, Cecconi F (2007) Ambra1 regu-
lates autophagy and development of the nervous system. Nature
447:1121–1125
158. Itakura E, Kishi C, Inoue K, Mizushima N (2008) Beclin 1 forms
two distinct phosphatidylinositol 3-kinase complexes with
mammalian Atg14 and UVRAG. Mol Biol Cell 19:5360–5372
159. Matsunaga K, Saitoh T, Tabata K, Omori H, Satoh T, Kurotori N,
Maejima I, Shirahama-Noda K, Ichimura T, Isobe T, Akira S,
Noda T, Yoshimori T (2009) Two Beclin 1-binding proteins,
Atg14L and Rubicon, reciprocally regulate autophagy at different
stages. Nat Cell Biol 11:385–396
160. Zhong Y, Wang QJ, Li X, Yan Y, Backer JM, Chait BT, Heintz N,
Yue Z (2009) Distinct regulation of autophagic activity by Atg14L
and Rubicon associated with Beclin 1-phosphatidylinositol-3-
kinase complex. Nat Cell Biol 11:468–476
161. Pickford F, Masliah E, Britschgi M, Lucin K, Narasimhan R,
Jaeger PA, Small S, Spencer B, Rockenstein E, Levine B,
Wyss-Coray T (2008) The autophagy-related protein beclin 1
shows reduced expression in early Alzheimer disease and regulates
amyloid beta accumulation in mice. J Clin Invest 118:2190–2199
162. Jaeger PA, Pickford F, Sun CH, Lucin KM, Masliah E, Wyss-
Coray T (2010) Regulation of amyloid precursor protein process-
ing by the Beclin 1 complex. PLoS One 5:e11102
163. Lee JH, Yu WH, Kumar A, Lee S, Mohan PS, Peterhoff CM,
Wolfe DM, Martinez-Vicente M, Massey AC, Sovak G,
Uchiyama Y, Westaway D, Cuervo AM, Nixon RA (2010)
Lysosomal proteolysis and autophagy require presenilin 1 and
are disrupted by Alzheimer-related PS1 mutations. Cell
141:1146–1158
164. Cataldo AM, Peterhoff CM, Troncoso JC, Gomez-Isla T, Hyman
BT, Nixon RA (2000) Endocytic pathway abnormalities precede
amyloid beta deposition in sporadic Alzheimer’s disease and
Down syndrome: differential effects of APOE genotype and
presenilin mutations. Am J Pathol 157:277–286
165. Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G,
Johnson-Wood K, Lee M, Seubert P, Davis A, Kholodenko D,
Motter R, Sherrington R, Perry B, Yao H, Strome R, Lieberburg I,
Rommens J, Kim S, Schenk D, Fraser P, St George Hyslop P,
Selkoe DJ (1997) Mutant presenilins of Alzheimer’s disease
increase production of 42-residue amyloid beta-protein in both
transfected cells and transgenic mice. Nat Med 3:67–72
54 Mol Neurobiol (2012) 46:41–54
